LFWD vs GMED

For growth investors, Globus Medical, Inc.

(GMED) is the stronger pick with 16. 7% revenue growth year-over-year, versus -14. 1% for Lifeward Ltd. (LFWD). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Lifeward Ltd. (LFWD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +16. 1%, compared to -95. 2% for Lifeward Ltd. (LFWD). Over 10 years, the gap is even starker: GMED returned +264. 4% versus LFWD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lifeward Ltd.

(LFWD) is the lower-risk stock at 1. 24β versus Globus Medical, Inc. 's 1. 29β — meaning GMED is approximately 4% more volatile than LFWD relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 19% for Lifeward Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Globus Medical, Inc.

(GMED) is pulling ahead at 16. 7% versus -14. 1% for Lifeward Ltd. (LFWD). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 57. 1% for Lifeward Ltd.. Over a 3-year CAGR, LFWD leads at 58. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -90. 4% for Lifeward Ltd. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -76. 7% for LFWD. At the gross margin level — before operating expenses — GMED leads at 67. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LFWD: 59.

0% to $10. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Globus Medical, Inc.

(GMED) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29), +264. 4% 10Y return). Both have compounded well over 10 years (GMED: +264. 4%, LFWD: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFWD is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.